VAXXAS’ new needle-free
vaccine delivery system,
Nanopatch, has been awarded the
Best Venture Capital Investment at
the 2012 Vaccine Industry
Excellence Awards.
The Nanopatch was created by
Prof Mark Kendall and his team at
University of Queensland’s
Australian Institute for
Bioengineering and Nanotechnology,
and was made commercially viable
by a $15m investment in Vaxxas Pty
Ltd by OneVentures, Brandon
Capital Partners, the Medical
Research Commercialisation Fund,
and US-based HealthCare Ventures.The above article was sent to subscribers in Pharmacy Daily's issue from 18 Apr 12 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 18 Apr 12
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
AUSTRALIA’S public hospitals are facing their lengthiest wait times on record for planned surgeries, with emergency departments struggling under access blockages, according to the latest annual Public Hospital Report Card by the Australian Medical Association (AMA).
THE University of South Australia has released a new study to help healthcare workers better support women with persistent pelvic pain, including symptoms that are suggestive of gynaecological, lower urinary tract, bowel, sexual, and pelvic floor dysfunction.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.